Vertex Pharmaceuticals Incorporated
VRTX
$448.29
$13.123.02%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.99B | 3.19B | 3.08B | 2.94B | 2.76B |
| Total Other Revenue | -- | 0.00 | -- | 20.70M | 10.00M |
| Total Revenue | 2.99B | 3.19B | 3.08B | 2.96B | 2.77B |
| Cost of Revenue | 1.35B | 1.44B | 1.39B | 1.39B | 1.34B |
| Gross Profit | 1.63B | 1.75B | 1.68B | 1.58B | 1.43B |
| SG&A Expenses | 493.70M | 487.00M | 445.10M | 424.60M | 396.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.85B | 1.93B | 1.84B | 1.81B | 1.74B |
| Operating Income | 1.14B | 1.26B | 1.24B | 1.15B | 1.03B |
| Income Before Tax | 1.25B | 1.33B | 1.30B | 1.28B | 730.40M |
| Income Tax Expenses | 221.50M | 139.90M | 215.90M | 250.10M | 84.10M |
| Earnings from Continuing Operations | 1.03B | 1.19B | 1.08B | 1.03B | 646.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.03B | 1.19B | 1.08B | 1.03B | 646.30M |
| EBIT | 1.14B | 1.26B | 1.24B | 1.15B | 1.03B |
| EBITDA | 1.19B | 1.29B | 1.29B | 1.21B | 1.08B |
| EPS Basic | 4.06 | 4.69 | 4.24 | 4.02 | 2.52 |
| Normalized Basic EPS | 3.07 | 3.40 | 3.31 | 3.12 | 2.79 |
| EPS Diluted | 4.02 | 4.65 | 4.20 | 3.99 | 2.49 |
| Normalized Diluted EPS | 3.05 | 3.37 | 3.28 | 3.09 | 2.76 |
| Average Basic Shares Outstanding | 254.10M | 253.90M | 255.60M | 256.70M | 256.90M |
| Average Diluted Shares Outstanding | 256.30M | 256.10M | 257.60M | 258.90M | 259.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |